Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)
نویسندگان
چکیده
منابع مشابه
Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn's disease. Crohn's disease is initiated by an innate immune response, which eventuates in a T-cell driven process, characterized by a T-helper cell 1 type cytokine profile. Several new treatments now focus on suppressing T-cell differentiation or T-cell inflammation. Sin...
متن کاملTargeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
Anti-TNFalpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFalpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNFalpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this ne...
متن کاملCertolizumab pegol in the treatment of Crohn's disease.
INTRODUCTION The introduction of antibodies directed against tumour necrosis factor (anti-TNF) has dramatically changed the concept of treating patients with Crohn's disease (CD). Unfortunately, the long-term efficacy of anti-TNF agents may be hampered by immunogenicity. The availability of more anti-TNF agents in the therapeutic armamentarium would therefore be of great benefit in patients loo...
متن کاملCertolizumab pegol for the treatment of Crohn's disease.
In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program suggest that certolizumab pegol offers rapid and sustained remission of moderate ...
متن کاملNew biologics in the management of Crohn’s disease: focus on certolizumab pegol
Crohn's disease (CD) is a chronic inflammatory condition involving the gastrointestinal tract characterized by recurrent exacerbations and remission. The disease frequently occurs in the lower part of the small bowel, but can affect any part of the digestive tract, from the mouth to the anus. The traditional goals of treatment of Crohn's disease were to induce and maintain clinical remission. M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Nanomedicine
سال: 2007
ISSN: 1176-9114
DOI: 10.2147/nano.2007.2.1.39